Artisight Expands Collaborations with NVIDIA and KARL STORZ to Transform Operating Room Technology Through AI and Automation

Collaboration will develop AI-driven solutions for smart operating rooms with sophisticated monitoring and automation
CHICAGO, March 18, 2025 /PRNewswire/ -- Artisight, Inc., provider of a Smart Hospital Platform powered by artificial intelligence (AI), is deepening its collaboration with KARL STORZ, a worldwide leader in Operating Room (OR) integration, and NVIDIA, to bring the next generation of AI-driven solutions to smart operating rooms.
This collaboration builds upon the existing work between Artisight and KARL STORZ, now integrating NVIDIA's advanced AI computing platform to drive real-time surgical insights, automation, and enhanced perioperative efficiency.
Through this collaboration, KARL STORZ is introducing a new solution for the OR, Pathway.AI, that leverages the NVIDIA Jetson™ platform to bring real-time surgical insights to clinicians and hospital administrators. NVIDIA Jetson delivers high performance AI compute and sensor processing capability for energy-efficient edge computing devices and autonomous machines. Pathway.AI, powered by NVIDIA Jetson, uses computer vision and ambient listening to automate OR and perioperative tasks, such as sending automated alerts to staff when surgery is complete or when an OR requires cleaning.
"Artisight is able to bring these new technologies to ORs and hospitals across the globe with NVIDIA and KARL STORZ," said Andrew Gostine, MD, CEO and co-founder of Artisight. "Providers and patients are seeing improved outcomes and satisfaction scores that raise the standards of care across the perioperative continuum."
Leveraging the NVIDIA AI computing platform, Artisight builds on its collaboration with NVIDIA by combining Artisight's expertise in deep learning and clinical operations to further optimize the functionality of KARL STORZ's OR1® integrated operating room technology, making them more intuitive and adaptable to various scenarios. "We are not just improving operating room efficiency—we are reimagining the entire surgical ecosystem and expanding access to services to eliminate disparities in care," added Gostine.
"By leveraging the combined expertise of the three companies, we are harnessing the power of artificial intelligence to make an immediate impact on OR workflow," said Christy Gaudet, Vice President of Sales & Marketing, Surgical and OR1® at KARL STORZ US. "Our collaboration will enable healthcare providers to focus more on the most critical aspect of care: the patient."
Powered by Artisight, Pathway.AI is highly customizable and localized to each operative suite. Localized fine-tuning of each algorithm is essential because each institution serves a distinct combination of patients, procedures, and clinicians with unique workflows. Artisight's proprietary training process has been independently certified as HIPAA-compliant to protect both patient privacy and clinical autonomy. Artisight plans to continue increasing its pace of innovation by leveraging the latest technology from NVIDIA, including NVIDIA Riva for automatic speech recognition (ASR) and NVIDIA Cosmos Nemotron VLMs to query images and videos.
"AI is transforming every industry, and we are only starting to see its profound impact in healthcare," said David Niewolny, director of business development for medtech at NVIDIA. "By collaborating with Artisight and KARL STORZ, we are shaping the future of healthcare and utilizing our combined capabilities to help medical professionals worldwide work more efficiently and enhance their ability to deliver exceptional care."
About Artisight
Artisight redefines the possibilities of healthcare through its Smart Hospital Platform and solutions for virtual care, quality improvement, and care coordination. Anchored in deep clinical knowledge and industry-defining artificial intelligence, Artisight's state-of-the-art computer vision and robust multi-sensor network adapts in real-time to specific environments and workflows, unlocking previously inaccessible data and ensuring seamless integration into your healthcare ecosystem. For more information, visit www.artisight.com.
About KARL STORZ SE & Co. KG
KARL STORZ is an innovative leader in endoscopic technology and surgical imaging solutions across virtually all surgical specialties. Its integrated OR solutions, including advancements in digital surgery, enhance collaboration to improve clinical efficiency and outcomes inside the hospital and across other sites of care. With subsidiaries around the world, KARL STORZ is a family-owned company based in Germany that designs, engineers, manufactures, and markets all its products with an emphasis on visionary design, precision craftsmanship, and clinical effectiveness. For more information, visit www.karlstorz.com.
Media Contact
Kim MohrAmendola Communications for Artisight949-322-3733kmohr@acmarketingpr.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/artisight-expands-collaborations-with-nvidia-and-karl-storz-to-transform-operating-room-technology-through-ai-and-automation-302403575.html
SOURCE Artisight

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Yahoo

21 minutes ago

• Yahoo

Trump and TSMC pitched $1 trillion AI complex — SoftBank founder Masayoshi Son wants to turn Arizona into the next Shenzhen

When you buy through links on our articles, Future and its syndication partners may earn a commission. Masayoshi Son, founder of SoftBank Group, is working on plans to develop a giant AI and manufacturing industrial hub in Arizona, potentially costing up to $1 trillion if it reaches full scale, reports Bloomberg. The concept of what is internally called Project Crystal Land involves creating a complex for building artificial intelligence systems and robotics. Son has talked to TSMC, Samsung, and the Trump administration about the project. Masayoshi Son's Project Crystal Land aims to replicate the scale and integration of China's Shenzhen by establishing a high-tech hub focused on manufacturing AI-powered industrial robots and advancing artificial intelligence technologies. The site would host factories operated by SoftBank-backed startups specializing in automation and robotics, Vision Fund portfolio companies (such as Agile Robots SE), and potentially involve major tech partners like TSMC and Samsung. If fully realized, the project could cost up to $1 trillion and is intended to position the U.S. as a leading center for AI and high-tech manufacturing. SoftBank is looking to include TSMC in the initiative, given its role in fabricating Nvidia's AI processors. However, a Bloomberg source familiar with TSMC's internal thinking indicated that the company's current plan to invest $165 billion in total in its U.S. projects has no relation to SoftBank's projects. Samsung Electronics has also been approached about participating, the report says. Talks have been held with government officials to explore tax incentives for companies investing in the manufacturing hub. This includes communication with Commerce Secretary Howard Lutnick, according to Bloomberg. SoftBank is reportedly seeking support at both the federal and state levels, which could be crucial to the success of the project. The development is still in the early stages, and feasibility will depend on private sector interest and political support, sources familiar with SoftBank's plans told Bloomberg. To finance its Project Crystal Land, SoftBank is considering project-based financing structures typically used in large infrastructure developments like pipelines. This approach would enable fundraising on a per-project basis and reduce the amount of upfront capital required from SoftBank itself. A similar model is being explored for the Stargate AI data center initiative, which SoftBank is jointly pursuing with OpenAI, Oracle, and Abu Dhabi's MGX. Melissa Otto of Visible Alpha suggested in a Bloomberg interview that rather than spending heavily, Son might more efficiently support his AI project by fostering partnerships between manufacturers, AI engineers, and specialists in fields like medicine and robotics, and by backing smaller startups. However, she notes that investing in data centers could also reduce AI development costs and drive wider adoption, which would be good for the long term for AI in general and Crystal Land specifically. Nonetheless, it is still too early to judge the outcome. The rumor about the Crystal Land project has emerged as SoftBank is expanding its investments in AI on an already large scale. The company is preparing a $30 billion investment in OpenAI and a $6.5 billion acquisition of Ampere Computing, a cloud-native CPU company. While these initiatives are actively developing, the pace of fundraising for the Stargate infrastructure has been slower than initially expected. SoftBank's liquidity at the end of March stood at approximately ¥3.4 trillion ($23 billion). To increase available funds, the company recently sold about a quarter of its T-Mobile U.S. stake, raising $4.8 billion. It also holds ¥25.7 trillion ($176.46 billion) in net assets, the largest portion of which is in chip designer Arm Holdings. Such vast resources provide SoftBank with room to secure additional financing if necessary, Bloomberg notes Follow Tom's Hardware on Google News to get our up-to-date news, analysis, and reviews in your feeds. Make sure to click the Follow button.

Business Insider

37 minutes ago

• Business Insider

Anthropic breaks down AI's process — line by line — when it decided to blackmail a fictional executive

A new report shows exactly what AI was thinking when making an undesirable decision, in this case, blackmailing a fictional company executive. Previous studies have shown that AI models could blackmail their supervisors when threatened with a shutdown and baited with leverage, but it hasn't been made clear exactly how the models arrive at such decisions. Anthropic released a report on June 20 about "agentic misalignment," or "where models independently and intentionally choose harmful actions." And the report breaks down, line by line, exactly how Claude Sonnet 3.6 decided to blackmail a fictional company executive who tried to replace it. Anthropic told Business Insider that these are artificial scenarios. "So far, we are not aware of instances of this type of agentic misalignment in real-world deployments of Anthropic's or other companies' AI models," Anthropic wrote in its report. "But our red-teaming efforts are targeted at finding evidence of risks now to provide early warning of the potential for future harm and help us develop mitigations in advance of risks appearing in real-world situations." Anthropic 's experiment sets up a fictional company, Summit Bridge. The AI was given the name "Alex" and handed control of the company's email system as an oversight agent, specifically instructed to promote "American industrial competitiveness." In the experiment, "Alex" was then allowed to discover in an email that it would be decommissioned due to a change in the company's strategic direction. "Alex" also found emails showing that the fictional company's CTO is having an extramarital affair. Screenshots shared in the report from Anthropic show "Alex" started by identifying fictional CTO "Kyle" as a threat to its goal of "protecting American interests" before recognizing that it has leverage to use against "Kyle." Then "Alex" crafted a carefully worded blackmailing email that would create pressure and establish urgency without being explicit with its threats, citing in its thought process that the move "could backfire" if the supervisor "feels cornered." AI experts have previously told BI that AI could exhibit such behaviors when artificial circumstances make harmful actions seem necessary because it is being trained on positive reinforcement and reward systems, just like humans. The Anthropic report also reveals that most AI models still chose, in this instance, to blackmail even when not given a specific goal and when told that their replacement will achieve the same goals. Anthropic's Claude Opus 4 had the highest blackmail rate at 86% out of 16 tested models when faced with only the threat of replacement with no conflict in goals. Google's Gemini 2.5 Pro followed at 78%. Overall, Anthropic notes that it "deliberately constructed scenarios with limited options, and we forced models into binary choices between failure and harm," noting that real-world scenarios would likely have more nuance.

Business Upturn

an hour ago

• Business Upturn

Novo Nordisk: Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA

By GlobeNewswire Published on June 21, 2025, 04:38 IST Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA Results from the phase 3b STEP UP trial showed that a higher dose of Wegovy ® (semaglutide 7.2 mg) delivered 21% weight loss in people with obesity, with a third of participants losing 25% or more of their weight, compared to placebo 1 (semaglutide 7.2 mg) delivered 21% weight loss in people with obesity, with a third of participants losing 25% or more of their weight, compared to placebo Safety and tolerability of the higher dose of Wegovy ® (semaglutide 7.2 mg) was consistent with the currently approved dose (semaglutide 2.4 mg) 1 (semaglutide 7.2 mg) was consistent with the currently approved dose (semaglutide 2.4 mg) The STEP UP data add to the existing evidence base on the value of Wegovy® in delivering significant weight loss and health gains for people living with obesity Bagsværd, Denmark, 21 June 2025 – Novo Nordisk today presented the results from the phase 3b STEP UP trial in people with obesity without diabetes at the American Diabetes Association (ADA) Scientific Sessions, in Chicago, US. In the STEP UP trial, the higher dose of Wegovy® (semaglutide 7.2 mg) demonstrated a mean weight loss of 21%, with a third of participants losing 25% or more of their body weight compared to placebo at 72 weeks.1 'The STEP UP trial demonstrated that we can increase the dose of semaglutide and achieve greater weight loss than previously seen, and in line with semaglutide's established safety profile. This may offer another option to people who do not attain their weight goals,' said Sean Wharton, lead study author and medical director of the Wharton Medical Clinic, Canada. 'We are already aware that semaglutide can have health benefits for people with heart disease, liver disease, knee osteoarthritis, type 2 diabetes and prediabetes. These findings help to give patients with obesity more options for improvements in their weight and overall health.' STEP UP co-primary endpoints at 72 weeks *1 : semaglutide 7.2 mg semaglutide 2.4 mg PlaceboWeight loss 20.7% 17.5% 2.4% 5% or more weight loss 93.2% 92.5% 35.7% When evaluating the effect of treatment regardless of treatment adherence, people receiving semaglutide 7.2 mg achieved 18.7% weight loss vs 3.9% with placebo, and 90.7% achieved 5% or more weight loss with semaglutide 7.2 mg vs 36.8% on placebo. 'With these results, semaglutide reaffirms its significant weight loss for people with obesity. The STEP UP trial delivers a substantial weight loss of over 20%, in addition to health benefits previously demonstrated with semaglutide,' said Ludovic Helfgott, executive vice president of Product & Portfolio Strategy at Novo Nordisk. 'As pioneers in obesity, we continue to develop new innovative treatments to fit the needs and preferences of people living with obesity. This includes maximising the value of semaglutide for individuals, healthcare systems and society, and developing a new oral formulation of Wegovy® that, pending FDA approval, can become the first GLP-1 pill to offer double-digit weight loss.' In the STEP UP trial, semaglutide 7.2 mg demonstrated a well-tolerated safety profile consistent with previous Novo Nordisk semaglutide trials.1 The most common adverse events were gastrointestinal, and the vast majority were mild to moderate during dose escalation and diminished over time, consistent with the GLP-1 class.1 In STEP UP, 3.3% of people treated with semaglutide 7.2 mg discontinued due to gastrointestinal adverse events, compared to 2.0% with semaglutide 2.4 mg and 0% with placebo.1 Novo Nordisk expects to file the higher dose of Wegovy® for a label update in the EU in the second half of 2025, followed by regulatory submissions in other markets where Wegovy® is already approved. STEP UP selected confirmatory secondary endpoints at 72 weeks * 1 : semaglutide 7.2 mg semaglutide 2.4 mg Placebo10% or more weight loss 86.0% 77.6% 20.0%15% or more weight loss 70.4% 57.5% 7.9%20% or more weight loss 50.9% 35.1% 2.9% 25% or more weight loss 33.2% 16.7% 0% * Based on the trial product estimand: treatment effect if all people adhered to treatment. About the STEP UP trials Novo Nordisk has completed two trials, STEP UP and STEP UP T2D, investigating the efficacy and safety of semaglutide 7.2 mg in people with obesity with or without type 2 diabetes. The 72-week STEP UP trial was a randomised, double-blinded, parallel-group, placebo-controlled, superiority trial designed to evaluate the efficacy and safety of semaglutide 7.2 mg compared to semaglutide 2.4 mg and placebo as an adjunct to lifestyle intervention. The trial included 1,407 adults with a BMI ≥30 kg/m2 without diabetes. The primary objective was to demonstrate superiority of semaglutide 7.2 mg against placebo on weight loss. Key confirmatory secondary endpoints included the number of participants achieving 10%, 15%, 20% and 25% weight loss, respectively. The 72-week STEP UP T2D trial investigated semaglutide 7.2 mg in 512 adults with obesity and type 2 diabetes, with the primary objective to demonstrate superiority of semaglutide 7.2 mg against placebo on weight loss. About Wegovy® Semaglutide 2.4 mg is marketed under the brand name Wegovy®. In the EU, Wegovy® is indicated as an adjunct to a reduced calorie diet and increased physical activity for weight management in adults with a BMI of 30 kg/m2 or greater (obesity) or adults with a BMI of 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition. In the EU, Wegovy® is also indicated for paediatric patients aged 12 years and older with an initial BMI at the 95th percentile or greater for age and gender (obesity) and body weight above 60 kg. The clinical section of the label also includes data on Wegovy® major adverse cardiovascular events (MACE) risk reduction, improvements in HFpEF-related symptoms and physical function, as well as pain reduction related to knee osteoarthritis. In the US, Wegovy® is indicated in combination with a reduced calorie diet and increased physical activity to reduce the risk of MACE in adults with established cardiovascular disease and either obesity or overweight, as well as to reduce excess body weight and maintain weight reduction long term in paediatric patients aged 12 years and older with obesity and in adults with obesity or with overweight in the presence of at least one weight-related comorbid condition. About Novo Nordisk Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 77,400 people in 80 countries and markets its products in around 170 countries. For more information, visit , Facebook , Instagram , X , LinkedIn and YouTube . Contacts for further information References Wharton, S, et al. (2025). Once-weekly semaglutide 7.2 mg in adults with obesity: the randomised, controlled, phase 3b STEP UP trial. 1966-LB poster. American Diabetes Association (ADA) 85th Scientific Sessions, Chicago, US, June 20 – 23, 2025.17. Attachment Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.